Adaptive Biotechnologies Appoints New CMO, Director
Ticker: ADPT · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1478320
| Field | Detail |
|---|---|
| Company | Adaptive Biotechnologies Corp (ADPT) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-appointment, personnel-change
TL;DR
Adaptive Bio names new CMO, adds a director to the board.
AI Summary
Adaptive Biotechnologies Corp. announced on April 1, 2024, the appointment of Dr. Jessica M. Lang as Chief Medical Officer and the election of Ms. Jennifer D. D. Fox to its Board of Directors. Additionally, the company entered into a new employment agreement with Dr. Lang, effective April 1, 2024, outlining her compensation and duties.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or leadership focus within its biotechnology operations.
Risk Assessment
Risk Level: low — The filing reports routine executive and board appointments, which typically carry low immediate risk.
Key Players & Entities
- Adaptive Biotechnologies Corp. (company) — Registrant
- Dr. Jessica M. Lang (person) — Appointed Chief Medical Officer
- Ms. Jennifer D. D. Fox (person) — Elected to Board of Directors
- April 1, 2024 (date) — Effective date of appointments and new agreement
- April 2, 2024 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Jessica M. Lang has been appointed as the new Chief Medical Officer.
When was Dr. Jessica M. Lang's new employment agreement effective?
Dr. Jessica M. Lang's new employment agreement was effective April 1, 2024.
Who has been elected to the Board of Directors?
Ms. Jennifer D. D. Fox has been elected to the Board of Directors.
What is the company's principal executive office address?
The company's principal executive office is located at 1165 Eastlake Avenue East, Seattle, Washington 98109.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 1, 2024.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-04-02 16:06:55
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ADPT The Nasdaq Stock Mar
Filing Documents
- d821049d8k.htm (8-K) — 21KB
- 0001193125-24-084748.txt ( ) — 136KB
- adpt-20240401.xsd (EX-101.SCH) — 3KB
- adpt-20240401_lab.xml (EX-101.LAB) — 17KB
- adpt-20240401_pre.xml (EX-101.PRE) — 11KB
- d821049d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADAPTIVE BIOTECHNOLOGIES CORPORATION Date: April 2, 2024 By: /chad robins/ Chad M. Robins, Chief Executive Officer